342 related articles for article (PubMed ID: 20095915)
21. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers.
Goff LW; Cardin DB; Whisenant JG; Du L; Koyama T; Dahlman KB; Salaria SN; Young RT; Ciombor KK; Gilbert J; Smith SJ; Chan E; Berlin J
Invest New Drugs; 2017 Feb; 35(1):95-104. PubMed ID: 27853997
[TBL] [Abstract][Full Text] [Related]
22. Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
Taïeb J; Bonyhay L; Golli L; Ducreux M; Boleslawski E; Tigaud JM; de Baere T; Mansourbakht T; Delgado MA; Hannoun L; Poynard T; Boige V
Cancer; 2003 Dec; 98(12):2664-70. PubMed ID: 14669287
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study.
Kakolyris S; Ziras N; Vamvakas L; Varthalitis J; Papakotoulas P; Syrigos K; Vardakis N; Kalykaki A; Amarantidis K; Georgoulias V
Lung Cancer; 2006 Dec; 54(3):347-52. PubMed ID: 17030075
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
Woo SM; Lee WJ; Han SS; Park SJ; Kim TH; Koh YH; Kim HB; Hong EK; Park JW; Kim CM
Chemotherapy; 2012; 58(3):225-32. PubMed ID: 22831988
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
Kim ST; Kang JH; Lee J; Lee HW; Oh SY; Jang JS; Lee MA; Sohn BS; Yoon SY; Choi HJ; Hong JH; Kim MJ; Kim S; Park YS; Park JO; Lim HY
Ann Oncol; 2019 May; 30(5):788-795. PubMed ID: 30785198
[TBL] [Abstract][Full Text] [Related]
26. [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
Xie DR; Liang HL; Yang Q; Guo SS; Jiang ZM
Ai Zheng; 2007 Aug; 26(8):895-9. PubMed ID: 17697555
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
Elshebeiny M; Almorsy W
J Egypt Natl Canc Inst; 2016 Sep; 28(3):183-9. PubMed ID: 27237370
[TBL] [Abstract][Full Text] [Related]
28. Weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with recurrent and refractory ovarian cancer: a preliminary result of 19 cases.
Ikeda Y; Takano M; Oda K; Kouta H; Goto T; Kudoh K; Sasaki N; Kita T; Kikuchi Y
Int J Gynecol Cancer; 2013 Feb; 23(2):355-60. PubMed ID: 23358182
[TBL] [Abstract][Full Text] [Related]
29. Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
Pino MS; Milella M; Gelibter A; Sperduti I; De Marco S; Nuzzo C; Bria E; Carpanese L; Ruggeri EM; Carlini P; Cognetti F
Oncology; 2009; 76(4):254-61. PubMed ID: 19246950
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study.
Demols A; Peeters M; Polus M; Marechal R; Gay F; Monsaert E; Hendlisz A; Van Laethem JL
Br J Cancer; 2006 Feb; 94(4):481-5. PubMed ID: 16434988
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01).
Culine S; Fléchon A; Guillot A; Le Moulec S; Pouessel D; Rolland F; Ravaud A; Houédé N; Mignot L; Joly F; Oudard S; Gourgou S
Eur Urol; 2011 Dec; 60(6):1251-7. PubMed ID: 21924547
[TBL] [Abstract][Full Text] [Related]
32. A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.
Chen JS; Hsu C; Chiang NJ; Tsai CS; Tsou HH; Huang SF; Bai LY; Chang IC; Shiah HS; Ho CL; Yen CJ; Lee KD; Chiu CF; Rau KM; Yu MS; Yang Y; Hsieh RK; Chang JY; Shan YS; Chao Y; Chen LT;
Ann Oncol; 2015 May; 26(5):943-949. PubMed ID: 25632066
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer.
Shi SB; Wang M; Niu ZX; Tang XY; Liu QY
Pancreatology; 2012; 12(6):475-9. PubMed ID: 23217281
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Boeck S; Hoehler T; Seipelt G; Mahlberg R; Wein A; Hochhaus A; Boeck HP; Schmid B; Kettner E; Stauch M; Lordick F; Ko Y; Geissler M; Schoppmeyer K; Kojouharoff G; Golf A; Neugebauer S; Heinemann V
Ann Oncol; 2008 Feb; 19(2):340-7. PubMed ID: 17962204
[TBL] [Abstract][Full Text] [Related]
35. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
Fortune BE; Li X; Kosuri KV; Weatherby LM; Thomas JP; Bekaii-Saab TS
Oncology; 2009; 76(5):333-7. PubMed ID: 19307739
[TBL] [Abstract][Full Text] [Related]
36. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):985-90. PubMed ID: 23995699
[TBL] [Abstract][Full Text] [Related]
37. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience.
Manzione L; Romano R; Germano D
Oncology; 2007; 73(5-6):311-5. PubMed ID: 18493158
[TBL] [Abstract][Full Text] [Related]
38. A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
Weissman CH; Reynolds CH; Neubauer MA; Pritchard S; Kobina S; Asmar L
J Thorac Oncol; 2011 Feb; 6(2):358-64. PubMed ID: 21206386
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.
Wu Z; Gabrielson A; Hwang JJ; Pishvaian MJ; Weiner LM; Zhuang T; Ley L; Marshall JL; He AR
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1309-14. PubMed ID: 26507197
[TBL] [Abstract][Full Text] [Related]
40. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
